Comparative analysis of international prognostic indices in gray-zone lymphoma

Leuk Lymphoma. 2022 Apr;63(4):894-902. doi: 10.1080/10428194.2021.2010067. Epub 2021 Dec 2.

Abstract

Gray-zone lymphoma (GZL) reflects an aggressive B-cell neoplasm with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). The International Prognostic Index (IPI) and its derivatives (R-IPI, NCCN-IPI, and the Hasenclever IPS) have been established for DLBCL or cHL while the most suitable scoring system for GZL remains undetermined. In an exploratory multi-centric cohort of GZL (n = 61), we performed a comparative analysis of prognostic indices with regard to model fit and mutual concordance. The calculation of the corrected Akaike's information criterion (cAIC) and Harrel's concordance index (c-index) for each scoring system identified the NCCN-IPI to harbor the most convincing prognostic capabilities regarding both overall survival (OS) and progression-free survival (PFS) compared to its enhanced derivatives. The current results affirm the clinical utility of the NCCN-IPI and suggest its preferential use in clinical practice in GZL-patients.

Keywords: Gray-zone lymphoma; IPI; prognosis; risk stratification.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Hodgkin Disease* / diagnosis
  • Hodgkin Disease* / therapy
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Prognosis
  • Progression-Free Survival
  • Retrospective Studies